Comparative Efficacy, Safety, and Cost‐Utility of DPP‐4 Inhibitors and Metformin Combination Therapy in Type 2 Diabetes: A Systematic Review of Real‐World Clinical and Economic Outcomes

Key Points

• The central aim is to evaluate the effectiveness, safety, and cost-utility of DPP-4 inhibitors combined with metformin compared to metformin alone.
• Conducted a systematic review of real-world clinical data
• Analyzed economic outcomes and cost-effectiveness
• Compared HbA1c reductions between treatments
• DPP-4 inhibitors combined with metformin reduce HbA1c levels significantly
• Cost-effectiveness is lower compared to metformin monotherapy and free drugs
• Initiating treatment with metformin alone is recommended for better patient adherence